Feb 4, 2025
Why SARS-CoV-2 bounces back after antiviral treatment
The antiviral combination of nirmatrelvir and ritonavir (brand name Paxlovid) is an effective treatment for people with COVID-19 who have mild symptoms and face a high risk of hospitalization. For some of those people, however, the virus returns, and those patients may experience more symptoms and spread the virus to others.
Read More
Jan 24, 2025
Shionogi signs contract with Taiwan government to supply 'Xocova' for reserves
On the 22nd, Shionogi Pharmaceutical of Japan announced that it signed a contract with the Taiwanese government to supply the COVID-19 treatment 'Xocova' to Taiwan for stockpiling. Shionogi will receive up to 1 billion yen for a contract of approximately 2 years and will strengthen its business in overseas markets by establishing Xocova as one of its main products in Japan. On the same day, Shionogi announced that it had also received an application for approval of Xocova in Taiwan.
Read More
Jan 22, 2025
Electroacupuncture may aid in personalized ribavirin dosing for long COVID
Various devices are used to study the unique electrical properties of acupuncture points (APs), with Voll's electropuncture diagnostics (EAV) occupying a prominent role.
Read More